Published in J Clin Invest on September 01, 2007
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol (2008) 2.72
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (2008) 2.07
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest (2012) 1.86
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One (2010) 1.84
Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol (2009) 1.81
Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology (2012) 1.81
Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (2010) 1.60
Mitochondrial dysfunction in cancer. Front Oncol (2013) 1.57
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell (2014) 1.50
New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res (2010) 1.46
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett (2012) 1.36
BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions. Oncogene (2008) 1.32
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics (2010) 1.27
Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology (2013) 1.26
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med (2010) 1.23
Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol (2014) 1.17
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Alcohol, DNA methylation, and cancer. Alcohol Res (2013) 1.14
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis (2011) 1.14
Changes in the expression of methionine adenosyltransferase genes and S-adenosylmethionine homeostasis during hepatic stellate cell activation. Hepatology (2010) 1.13
Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol (2013) 1.10
Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci (2010) 1.10
The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell (2014) 1.10
Gene expression and hepatitis C virus infection. Gut (2008) 1.08
Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Rep (2015) 1.07
miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene (2013) 1.06
Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia (2011) 1.06
Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res (2010) 1.03
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget (2013) 1.03
Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology (2013) 1.02
Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis. Mol Oncol (2009) 1.01
Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med (2014) 0.99
DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol (2014) 0.99
Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J Gastroenterol (2010) 0.99
Epigenetics: principles and practice. Dig Dis (2011) 0.98
Mitophagy and cancer. Cancer Metab (2015) 0.95
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer (2010) 0.93
CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget (2014) 0.93
Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. Carcinogenesis (2013) 0.92
Mechanisms and biology of B-cell leukemia/lymphoma 2/adenovirus E1B interacting protein 3 and Nip-like protein X. Antioxid Redox Signal (2011) 0.90
In Posidonia oceanica cadmium induces changes in DNA methylation and chromatin patterning. J Exp Bot (2011) 0.90
S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci (2010) 0.89
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma. Lab Invest (2013) 0.88
Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget (2014) 0.87
Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. Liver Int (2014) 0.87
Mechanisms of peroxisome proliferator-induced DNA hypomethylation in rat liver. Mutat Res (2008) 0.86
IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Mol Cancer (2012) 0.86
Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol (2014) 0.86
Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One (2013) 0.85
An integrated analysis of SOCS1 down-regulation in HBV infection-related hepatocellular carcinoma. J Viral Hepat (2014) 0.84
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis (2013) 0.83
Evolving therapies in the treatment of hepatocellular carcinoma. Biologics (2008) 0.83
Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma. Oncogenesis (2012) 0.83
Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). Oncol Lett (2014) 0.83
DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis. PLoS One (2013) 0.83
Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure. World J Hepatol (2012) 0.81
Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J Gastroenterol (2008) 0.81
Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice. BMC Cancer (2011) 0.81
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget (2015) 0.81
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
Low Expression of LDHB Correlates With Unfavorable Survival in Hepatocellular Carcinoma: Strobe-Compliant Article. Medicine (Baltimore) (2015) 0.81
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. PLoS One (2016) 0.81
Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis. Oncotarget (2015) 0.80
DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression. Cancer Res (2016) 0.80
SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection-Related Hepatocellular Carcinoma. Int J Mol Sci (2015) 0.80
Array-based profiling of the differential methylation status of CpG islands in hepatocellular carcinoma cell lines. Oncol Lett (2010) 0.80
DNA methylation and apoptosis resistance in cancer cells. Cells (2013) 0.79
Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disord (2014) 0.79
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol (2015) 0.79
Identifying genes progressively silenced in preneoplastic and neoplastic liver tissues. Int J Comput Biol Drug Des (2010) 0.79
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Sci Signal (2016) 0.78
Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma. J Korean Med Sci (2012) 0.78
Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. J Gastroenterol (2016) 0.78
Epigenetic impact of infection on carcinogenesis: mechanisms and applications. Genome Med (2016) 0.78
Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood (2016) 0.78
Nix Nought Nothing: fairy tale or real deal. J Mol Cell Cardiol (2010) 0.77
The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection. Front Microbiol (2016) 0.77
Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. PLoS One (2013) 0.77
An Overview of Biomarkers and Molecular Signatures in HCC. Cancers (Basel) (2010) 0.77
Zebrafish as an In Vivo Model to Assess Epigenetic Effects of Ionizing Radiation. Int J Mol Sci (2016) 0.77
Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics (2010) 0.77
Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice. Liver Int (2012) 0.77
Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma. PLoS One (2014) 0.77
Hypermethylation and Expression Silencing of PDCD4 Gene in Hepatocellular Carcinoma: A Consort Study. Medicine (Baltimore) (2016) 0.76
Epigenetic regulation in hepatocellular carcinoma requires long noncoding RNAs. Biomed Res Int (2015) 0.76
Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci (2014) 0.76
Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. Mol Biol Int (2012) 0.76
Expanding perspectives on the significance of mitophagy in cancer. Semin Cancer Biol (2017) 0.76
The epigenomics of cancer. Cell (2007) 30.91
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Simplified mammalian DNA isolation procedure. Nucleic Acids Res (1991) 12.56
COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res (1997) 9.94
The epigenetic progenitor origin of human cancer. Nat Rev Genet (2006) 9.65
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet (2000) 5.50
The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res (1999) 4.74
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
DNA hypomethylation and human diseases. Biochim Biophys Acta (2006) 4.31
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell (2004) 4.23
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
DNA hypomethylation leads to elevated mutation rates. Nature (1998) 3.60
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol (2004) 3.46
The epigenetics of cancer etiology. Semin Cancer Biol (2004) 3.24
Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. Oncogene (1989) 2.67
A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res (2002) 2.65
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol (2003) 2.36
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis (2003) 1.98
A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem Biophys Res Commun (1999) 1.77
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A (2002) 1.73
Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology (2001) 1.67
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer (2002) 1.63
Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology (2006) 1.55
Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology (2002) 1.55
Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem (2000) 1.53
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene (2004) 1.51
Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res (2001) 1.47
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res (2007) 1.45
The random amplified polymorphic DNA (RAPD) assay and related techniques applied to genotoxicity and carcinogenesis studies: a critical review. Mutat Res (2006) 1.40
Distinct methylation profiles of glioma subtypes. Int J Cancer (2003) 1.38
Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer (1999) 1.38
Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology (2004) 1.35
Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res (2004) 1.35
Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta (2004) 1.35
Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res (2003) 1.34
Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene (2006) 1.34
Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33
Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem (2004) 1.30
Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer (1999) 1.28
Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res (2004) 1.25
Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res (1998) 1.23
Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res (2001) 1.22
DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol (2005) 1.20
Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Res (2004) 1.17
Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem (2002) 1.12
DNMT1 knockout delivers a strong blow to genome stability and cell viability. Nat Genet (2007) 1.12
Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene (2004) 1.10
Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol (2002) 1.05
Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther (2006) 1.04
DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene (2001) 1.04
Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci U S A (2005) 1.00
RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res (2005) 0.99
Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. J Biol Chem (2001) 0.97
CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene (2004) 0.96
Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol (2005) 0.91
Frequent chromosomal instability but no microsatellite instability in hepatocellular carcinomas. Int J Oncol (2000) 0.80
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology (2010) 2.48
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell (2011) 2.10
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
Functional genomics of hepatocellular carcinoma. Hepatology (2006) 2.02
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene (2004) 1.90
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol (2013) 1.72
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene (2004) 1.65
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol (2009) 1.60
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell (2002) 1.57
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest (2011) 1.52
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene (2003) 1.52
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett (2005) 1.45
Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A (2011) 1.41
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res (2008) 1.41
Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene (2005) 1.39
Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol (2008) 1.39
RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology (2007) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology (2004) 1.35
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology (2006) 1.34